• 1
    Dalmasso AP, Falk RJ, Raij L. The pathology of the terminal complement complexes. Complement Inflamm 1989;6:3648.
  • 2
    Podack ER, Kolb WP, Muller-Eberhard HJ. The SC5b-7 complex: formation, isolation, properties, and subunit composition. J Immunol 1977;119:20249.
  • 3
    Podack ER, Preissner KT, Muller-Eberhard HJ. Inhibition of C9 polymerization within the SC5b-9 complex of complement by S-protein. Acta Pathol Microbiol Immunol Scand Suppl 1984;284:8996.
  • 4
    Bhakdi S, Kaflcin R, Halstensen TS et al. Complement S-protein (vitronectin) is associated with cytolytic membrane-bound C5b-9 complexes. Clin Exp Immunol 1988;74:45964.
  • 5
    Preissner KT. Structure and biological role of vitronectin. Annu Rev Cell Biol 1991;7:275310.
  • 6
    Izumi M, Shimo-Oka T, Morishita N et al. Identification of the collagen-binding domain of vitronectin using monoclonal antibodies. Cell Struct Funct 1988;13:21725.
  • 7
    Tschopp J, Masson D. Inhibition of the lytic activity of perform (cytolysin) and of late complement components by proteoglycans. Molecular Immunol 1987;24:90713.
  • 8
    Pussell BA, Morris CA, Milis L et al. Inhibition of complement by protamine sulphate. Proc 16th. Int Complement Workshop, Cambridge, UK. Complement Inflamm 1992;8:214.
  • 9
    Tschopp J, Mollnes TE. Antigenic crossreactivity of the alpha subunit of complement component C8 with the cysteine rich domain shared by complement component C9 and low density lipoprotein receptor. Proc Nat Acad Sci USA 1986;83:42239.
  • 10
    Murphy BF, Saunders JR, O'Bryan MK et al. SP-40,40 is an inhibitor of C5b-6 initiated haemolysis. Int Immunol 1989;1:5514.
  • 11
    Yatohgo T, Izumi M, Kashiwagi H et al. Novel purification of vitronectin from human plasma by heparin affinity chromatography. Cell Struct Funct 1988;13:28192.
  • 12
    Jenne D, Stanley KK. Molecular cloning of S-protein, a link between complement, coagulation and cell substrate adhesion. EMBO J 1985;4:31537.
  • 13
    Underwood PA, Dalton BA, Steele JG et al. Antifibronectin antibodies that modify heparin binding and cell adhesion; evidence for a new cell binding site in the heparin binding region. J Cell Sci 1992;102:83345.
  • 14
    Harrison RA, Lachmann PJ. Complement technology. In: WeirDM, ed. Handbook of experimental immunology. Vol. I. Oxford : Blackwell. 1986:39.139.49.
  • 15
    Hayashi M, Akama T, Kono I et al. Activation of vitronectin (serum spreading factor)—binding of heparin by denaturing agents. J Biochem (Tokyo) 1985;98:11358.
  • 16
    Hogasen K, Mollnes TE, Harboe M. Polymerization of S-protein (vitronectin) in vitro. Proc 16th. Int Complement Workshop, Cambridge UK. Complement Inflamm 1991;8:160.
  • 17
    Tschopp J, Masson D, Schafer S et al. The heparin binding domain of S-protein/vitronectin binds to complement components C7, C8 and C9 and perform from cylolytic T-cclls and inhibits their lytic activities. Biochemistry 1988;27:41039.
  • 18
    De Boer H, Preissner KT, Bouma BN et al. Binding of vitronectin thrombin-antithrombin III complex to human endothelial cells is mediated by the heparin binding site of vitronectin. J Biol Chem 1992;267:22648.
  • 19
    Suzuki S, Oldberg A, Hayman EG et al. Complete ammo acid sequence of human vitronectin deduced from cDNA. Similarity of cell attachment sites in vitronectin and fibronectin. EMBO J 1985;4:251924.
  • 20
    Ishikawa M, Hayashi M. Activation of the collagen-binding of endogenous serum vitronectin by heating, urea and glycosaminoglycans. Biochim Biophys Acta 1992; 1121:1737.
  • 21
    Seinert D, Loskutoff DJ. Evidence that type I plasminogen activator inhibitor binds to the somatomedin B domain of vitronectin. J Biol Chem 1991;266:282430.
  • 22
    Preissner KT, Grulich-Henn J, Ehrlich HJ et al. Structural requirements for the extracellular interaction of plasminogen activator inhibitor I with endothelial cell matrix-associated vitronectin. J Biol Chem 1990;265:184908.